Track topics on Twitter Track topics that are important to you
Achaogen is a clinical-stage biopharmaceutical company focused on the discovery and development of antibiotics for the treatment of serious infections caused by multi-drug resistant, Gram-negative bacteria. The companyâs pipeline includes ACHN-490, an aminoglycoside currently being evaluated in a Phase 2 clinical study for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis, and late-stage preclinical programs with demonstrated in vivo efficacy against Gram-negative pathogens of concern including P. aeruginosa and A. baumannii. Resistance to available antibacterial therapies continues to rise at an alarming rate and Achaogen is applying its anticipatory science to meet this evolving need, developing drugs today intended to combat tomorrowâs resistant pathogens. Achaogen has established specialized capabilities to pursue the discovery and development of new antibiotics, and has funded its growth with a blend of private investments and non-dilutive funding from partnerships with the NIH, the United States Department of Defense, and others. For more information, please visit the companyâs website at www.achaogen.com.
In a multi-year collaboration, Achaogen Inc. and Crystal Bioscience Inc. are teaming up to discover monoclonal antibodies against multiple targets of interest to Achaogen.
* Achaogen Inc says contract revenue totaled $5.8 million for q1 of 2016 compared to $4.9 million for same period of 2015 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-...
* Achaogen and Crystal Bioscience enter into collaboration and license agreement to identify and develop antibodies for multiple targets Source text for Eikon: Further company coverage: (Bengalur...
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant ...
Trianni Inc. licensed Achaogen Inc. rights to its Trianni transgenic mouse platform.
Achaogen is a clinical-stage biopharmaceutical company focused on the discovery and development of antibiotics for the treatment of serious infections caused by multi-drug resista...
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections.Â...
We have published hundreds of Achaogen, Inc. news stories on BioPortfolio along with dozens of Achaogen, Inc. Clinical Trials and PubMed Articles about Achaogen, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Achaogen, Inc. Companies in our database. You can also find out about relevant Achaogen, Inc. Drugs and Medications on this site too.
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...